Q-omics provides the consensus-scored TRAV29DV5 profile across patient tissues and cancer cell-line models. TRAV29DV5 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, TRAV29DV5 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, TRAV29DV5 RNA expression shows 15,864 significant gene co-expression associations, with the highest sampling consensus in DLBC. Together, these results highlight HNSC, KIRC, and DLBC as cancer lineages where TRAV29DV5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRAV29DV5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRAV29DV5 survival associations across molecular data types. TRAV29DV5 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRAV29DV5 RNA expression–survival associations across cancer types. High TRAV29DV5 expression shows unfavorable associations in KIRP, but favorable associations in HNSC, SKCM, BRCA, UCEC and CESC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for TRAV29DV5 RNA expression.
This table summarizes TRAV29DV5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for TRAV29DV5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRAV29DV5 shows lower tumor expression in COAD, LUSC and THCA and higher tumor expression in KIRC, BRCA and STAD. The KIRC box plot shows higher TRAV29DV5 RNA expression in tumor versus normal tissue (log2 FC = +1.286, t-test p < 0.001).
This table shows molecular features associated with TRAV29DV5 in patient tissues and cancer cell lines. In patient samples, TRAV29DV5 shows the broadest associations at the RNA and protein expression levels, with DLBC recurring as the lineage with the largest associated feature set.
